Compare HYLN & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | AGMB |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | Belgium |
| Employees | 113 | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 576.2M |
| IPO Year | 2019 | 2024 |
| Metric | HYLN | AGMB |
|---|---|---|
| Price | $3.37 | $7.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $7.75 | ★ $37.67 |
| AVG Volume (30 Days) | ★ 1.4M | 106.8K |
| Earning Date | 11-10-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $334.53 | N/A |
| Revenue Next Year | $139.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.56 | $7.88 |
| 52 Week High | $8.49 | $17.82 |
| Indicator | HYLN | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.54 | 31.45 |
| Support Level | $3.16 | N/A |
| Resistance Level | $4.62 | $9.65 |
| Average True Range (ATR) | 0.18 | 0.63 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 47.85 | 4.62 |
Hyliion Holdings Corp designs and develops power generators for stationary and mobile applications and provides R&D service. It provides solutions that enable clean, flexible, and affordable electricity production. The company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies. Its products and services include: KARNO Power Modules which is a modular, fully enclosed, fuel-agnostic and fully integrated power generating solution.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.